Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Joseph G Joyce

Kathrin Ute Jansen

Michael P Neeper

Hugh A George

Kathryn J Hofmann

James C Cook, Iii

Chitrananda Abeygunawardana

Paul M Keller

Robert S Lowe

E Dale Lehman

John M Williams

Victor M Garsky

Michael Albert Winters

Luwy Kavuka Musey

Henry Z Markus

Patrick McHugh

Gene G Kinney

John W Shiver

Julie Marie Skinner

Jian He

William L McClements

Xiaoping Liang

Emily Wen

William J Smith

Leslie Cope

Charlotte C Ip

John E MacNair

Keith Roper

Qiuwei Xu

Jessica Ching-Yee Ling

Robert W Hepler

Craig T Przysiecki

Karen M Grimm

Catherine Lancaster

Hari Pujar

Kathryn J Hofman

Ernest Dale Lehman

Loren S Schultz

Mark Rosolowsky

Gene Kinney

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides frombacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

Enhancing immunogenicity ofpolysaccharide-protein conjugates

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A&#x3b2;, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A&#x3b2;. In another aspect, the immunogenic fragment of A&#x3b2; is capable of elevating plasma A&#x3b2; levels. The immunogenic fragments comprise linear or multivalent peptides of A&#x3b2;. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,&#x3b2;-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.

[object Object]

Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.

Protein delivery system using human papillomavirus virus-like particles

The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.

DNA encoding human papilloma virus type 18

Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1

Recombinant expression vectors encoding the L1 and L2 proteins of papillomavirus, methods of making and using the recombinant proteins and purified virus-like particles comprised of the recombinant proteins are provided.

Recombinant papillomavirus vaccines

The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.

Production of recombinant human papillomavirus type II protein utilizing

The present invention is directed to vaccines for human papillomavirus type 18 and derivatives thereof.

Recombinant human papillomavirus type 18 vaccine

Growing community of inventors

Lansdale, PA, United States of America

Joseph G Joyce